NRX Pharmaceuticals, Inc.
(NASDAQ : NRXP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.23%163.010.7%$1094.93m
MRKMerck & Co., Inc. 0.96%76.310.7%$1034.63m
LLYEli Lilly & Co. 7.57%233.541.1%$964.38m
PFEPfizer Inc. 0.22%39.140.9%$928.23m
ABBVAbbVie, Inc. 0.47%114.531.9%$721.51m
BMYBristol-Myers Squibb Co. 0.83%65.801.0%$630.11m
AZNAstraZeneca Plc 0.78%58.431.2%$392.45m
OGN 0.21%29.560.0%$269.19m
ORPHOrphazyme A/S 7.79%8.020.0%$227.06m
GSKGlaxoSmithKline Plc -0.21%39.770.2%$183.02m
NVSNovartis AG 0.25%92.620.2%$180.58m
NOVNNovan, Inc. 2.24%10.735.8%$135.47m
CVACCureVac NV 4.29%59.350.0%$115.74m
CNSTConstellation Pharmaceuticals, Inc. 0.27%33.850.0%$111.08m
RPRXRoyalty Pharma Plc 2.03%43.050.2%$106.09m

Company Profile

NRX Pharmaceuticals, Inc. is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company recently announced a commercial partnership with Relief Therapeutics Holding AG for global commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure (the NRx COVID-19 Drug). It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior the NRx Antidepressant Drug Regimen. The company is headquartered in Wilmington, DE.